Stay updated on Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.
Latest updates to the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a Georgia location to the Study Locations section and updated the page revision to v3.3.3; removed the Georgia Locations entry and the HHS Vulnerability Disclosure link.SummaryDifference0.2%
- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedThe page revision was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%
- Check54 days agoChange DetectedRemoved the government funding status notice from the page; this does not affect the study details, eligibility criteria, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check68 days agoChange DetectedNo additions or deletions affecting core study information were detected; observed differences are limited to layout/UI changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check97 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%
- Check104 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0, changing the page's revision label.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.